Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, announced terms for its IPO on Tuesday.
The South San Francisco, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. Insiders intend to purchase $40 million worth of shares in the offering (53% of the deal). At the midpoint of the proposed range, Harpoon Therapeutics would command a fully diluted market value of $377 million.
Harpoon Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol HARP. Citi and SVB Leerink are the joint bookrunners on the deal. It is expected to price during the week of February 4, 2019.
